Synthetic constrained peptide selectively binds and antagonizes death receptor 5

FEBS Journal

Volumn 277, Issue 7, 2010, Pages 1653-1665

  Vrielink, Johanna ^a   Heins, Mariette S ^a   Setroikromo, Rita ^a   Szegezdi, Eva ^b   Mullally, Margaret M ^a   Samali, Afshin ^b   Quax, Wim J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Apoptosis; DR5; Phage display; R2C16; TRAIL

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; PEPTIDE; PEPTIDE LIBRARY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TYROSYLCYSTEINYLLYSYLVALYLISOLEUCYLLEUCYLTHREONYLHISTIDYLARGINYLCYSTEINYLTYROSINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CARCINOMA CELL; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; PHAGE DISPLAY; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE;

APOPTOSIS; CELL LINE, TUMOR; CELL SEPARATION; COLONIC NEOPLASMS; DIMERIZATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JURKAT CELLS; KINETICS; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SURFACE PLASMON RESONANCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77949637145     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2010.07590.x     Document Type: Article

References (43)

1. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A et al. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest, 104, 155 162.
2. Huang Y, Erdmann N, Peng H, Zhao Y Zheng J (2005) The role of TNF related apoptosis-inducing ligand in neurodegenerative diseases. Cell Mol Immunol, 2, 113 122.
3. Aktas O, Waiczies S Zipp F (2007) Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets. J Neuroimmunol, 184, 17 26.
4. Uberti D, Ferrari-Toninelli G, Bonini SA, Sarnico I, Benarese M, Pizzi M, Benussi L, Ghidoni R, Binetti G, Spano P et al. (2007) Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity. Neuropsychopharmacology, 32, 872 880.
5. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J Dixit VM (1997) The receptor for the cytotoxic ligand TRAIL. Science, 276, 111 113.
6. Pan G, Ni J, Wei YF, Yu G, Gentz R Dixit VM (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 277, 815 818.
7. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI et al. (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 277, 818 821.
8. Walczak H, gli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA et al. (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J, 16, 5386 5397.
9. Budihardjo I, Oliver H, Lutter M, Luo X Wang X (1999) Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol, 15, 269 290.
10. LeBlanc HN Ashkenazi A (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ, 10, 66 75.
11. Pan G, Ni J, Yu G, Wei YF Dixit VM (1998) TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett, 424, 41 45.
12. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R et al. (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem, 273, 14363 14367.
13. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, Ashkenazi A de Vos AM (1999) Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell, 4, 563 571.
14. Mongkolsapaya J, Grimes JM, Chen N, Xu XN, Stuart DI, Jones EY Screaton GR (1999) Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol, 6, 1048 1053.
15. Cha SS, Sung BJ, Kim YA, Song YL, Kim HJ, Kim S, Lee MS Oh BH (2000) Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J Biol Chem, 275, 31171 31177.
16. Papoff G, Hausler P, Eramo A, Pagano MG, Di LG, Signore A Ruberti G (1999) Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J Biol Chem, 274, 38241 38250.
17. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL Lenardo MJ (2000) A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science, 288, 2351 2354.
18. Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D, Tsien RY Lenardo MJ (2000) Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science, 288, 2354 2357.
19. Thomas LR, Johnson RL, Reed JC Thorburn A (2004) The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation. J Biol Chem, 279, 52479 52486.
20. Guo Y, Chen C, Zheng Y, Zhang J, Tao X, Liu S, Zheng D Liu Y (2005) A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem, 280, 41940 41952.
21. Kim K, Fisher MJ, Xu SQ El-Deiry WS (2000) Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res, 6, 335 346.
22. Kurbanov BM, Geilen CC, Fecker LF, Orfanos CE Eberle J (2005) Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol, 125, 1010 1019.
23. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ Cohen GM (2005) TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res, 65, 11265 11270.
24. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG Ashkenazi A (2005) Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem, 280, 2205 2212.
25. van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, Serrano L Quax WJ (2006) Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA, 103, 8634 8639.
26. Reis CR, van der Sloot AM, Szegezdi E, Natoni A, Tur V, Cool RH, Samali A, Serrano L Quax WJ (2009) Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors (dagger). Biochemistry, 48, 2180 2191.
27. Tur V, van der Sloot AM, Reis CR, Szegezdi E, Cool RH, Samali A, Serrano L Quax WJ (2008) DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J Biol Chem, 283, 20560 20568.
28. Ladner RC, Sato AK, Gorzelany J de SM (2004) Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today, 9, 525 529.
29. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK Dower WJ (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science, 273, 458 464.
30. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, Davis AM, Tansik RL, Mattheakis LC, Boytos CM et al. (1997) Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science, 276, 1696 1699.
31. Sato A Sone S (2003) A peptide mimetic of human interferon (IFN)-beta. Biochem J, 371, 603 608.
32. Li B, Russell SJ, Compaan DM, Totpal K, Marsters SA, Ashkenazi A, Cochran AG, Hymowitz SG Sidhu SS (2006) Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists. J Mol Biol 361, 522 536.
33. Yanofsky SD, Baldwin DN, Butler JH, Holden FR, Jacobs JW, Balasubramanian P, Chinn JP, Cwirla SE, Peters-Bhatt E, Whitehorn EA et al. (1996) High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Proc Natl Acad Sci USA, 93, 7381 7386.
34. Binetruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, Plouet J, Derbin C, Perret G Mazie JC (2000) Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J, 19, 1525 1533.
35. England BP, Balasubramanian P, Uings I, Bethell S, Chen MJ, Schatz PJ, Yin Q, Chen YF, Whitehorn EA, Tsavaler A et al. (2000) A potent dimeric peptide antagonist of interleukin-5 that binds two interleukin-5 receptor alpha chains. Proc Natl Acad Sci USA, 97, 6862 6867.
36. Takasaki W, Kajino Y, Kajino K, Murali R Greene MI (1997) Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor. Nat Biotechnol, 15, 1266 1270.
37. Terskikh AV, Le Doussal JM, Crameri R, Fisch I, Mach JP Kajava AV (1997) "Peptabody": a new type of high avidity binding protein. Proc Natl Acad Sci USA, 94, 1663 1668.
38. Janssen M, Oyen WJ, Massuger LF, Frielink C, Dijkgraaf I, Edwards DS, Radjopadhye M, Corstens FH Boerman OC (2002) Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm, 17, 641 646.
39. O'Leary PD Hughes RA (2003) Design of potent peptide mimetics of brain-derived neurotrophic factor. J Biol Chem, 278, 25738 25744.
40. Aggarwal S, Harden JL Denmeade SR (2006) Synthesis and screening of a random dimeric peptide library using the one-bead-one-dimer combinatorial approach. Bioconjug Chem, 17, 335 340.
41. Kajiwara K, Saito A, Ogata S Tanihara M (2004) Synthetic peptides corresponding to ligand-binding region of death receptors, DR5, Fas, and TNFR, specifically inhibit cell death mediated by the death ligands, respectively. Biochim Biophys Acta, 1699, 131 137.
42. Aktas O, Smorodchenko A, Brocke S, Infante-Duarte C, Topphoff US, Vogt J, Prozorovski T, Meier S, Osmanova V, Pohl E et al. (2005) Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron, 46, 421 432.
43. van der Sloot AM, Mullally MM, Fernandez-Ballester G, Serrano L Quax WJ (2004) Stabilization of TRAIL, an all-beta-sheet multimeric protein, using computational redesign. Protein Eng Des Sel, 17, 673 680.